Patents Examined by L. F. Smith
-
Patent number: 6962706Abstract: This invention relates to a peptide selected from the group: FLLDADHNTFGSVIPATGPLFTGTASS LYSANFESLIPANADPVVTTQNIIVTG LYSANFEYLIPANADPVVTTQNIIVTG TNPEPASGKMWIAGDGGNQP RYDDFTFEAGKKYTFTMRRAGMGDGTD DDYVFEAGKKYHFLLLMKKMGSGDGTE TNPEPASGKMWIAGDGGNQPARYDDFTFEAGKKYTFTMRRAGMGDGTD NTFGSVIPATGPL PASGKMWIAGDG EAGKKYTFTMRRA EAGKKYHFLMKKM. It also relates to compositions and use of these peptides for treating and testing Porphyromonas gingialis.Type: GrantFiled: March 1, 2000Date of Patent: November 8, 2005Assignees: The University of Melbourne, CSL Limited, Victorian Dairy Industry AssociationInventors: Neil Martin O'Brien-Simpson, Eric Charles Reynolds
-
Patent number: 6951732Abstract: A series of genes from Streptococcus pyogenes are shown to encode products which are implicated in virulence. The identification of these genes therefore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application.Type: GrantFiled: December 22, 2000Date of Patent: October 4, 2005Assignee: VMAX Ltd.Inventors: Enda Elizabeth Clarke, Liqing Zhou, Jacqueline Elizabeth Shea, Robert Graham Feldman, David William Holden
-
Patent number: 6951631Abstract: A test kit for determining qualitatively or quantitatively the presence of one or more analytes in a fluid sample, comprising an assay device together with a reading device which engages with the assay device and wherein precisely located engagement of the assay device with the reading device is essential for accurate reading of the assay result, wherein precisely located engagement of the assay device with the reading device causes a ‘lock-and-key’ interaction, ie. a unique 3-dimensional interaction, between the assay device and reading initiation means of the reading device.Type: GrantFiled: September 23, 1997Date of Patent: October 4, 2005Assignee: Inverness Medical Switzerland GmbHInventors: Michael Catt, Peter Lenko, Michael T. Pearson
-
Patent number: 6936261Abstract: The present invention generally provides methods and vaccines for the prevention of diseases caused by Neisseria meningitidis bacteria, particularly serogroup B strains.Type: GrantFiled: July 27, 2001Date of Patent: August 30, 2005Assignee: Children's Hospital & Research Center at OaklandInventors: Dan Granoff, Gregory R. Moe
-
Patent number: 6936423Abstract: Lethal Toxin Neutralizing Factor has been isolated in purity from opossum serum by high pressure liquid chromatography (HPLC) fractionation. The amino acid sequence from the N-terminal for the first fifteen amino acids of LTNF-n is: Leu Lys Ala Met Asp Pro Thr Pro Pro Leu Trp Ile Lys Thr Glu. Antibodies to LTNF-n and synthetic peptides consisting of fifteen, ten and five amino acids from the N-terminal of the above sequence, designated as LTNF-15, LTNF-10 and LTNF-5 were produced by immunizing Balb/C mice to produce Anti-LTNF-n, Anti-LTNF-15, Anti-LTNF-10 and Anti-LTNF-5. The anti LTNF-n, anti-LTNF-15, anti-LTNF-10 and anti-LTNF-5 react immunologically with all types of toxins derived from animal, plant and bacteria and can be assayed by immunological in vitro test such as ELISA tests. Anti-LTNFs react roughly proportional to lethal dose of biological toxins under in vitro immunological ELISA test similar to the mouse bioassay test.Type: GrantFiled: April 27, 1999Date of Patent: August 30, 2005Inventors: Binie V. Lipps, Frederick W. Lipps
-
Patent number: 6919080Abstract: A novel peptide obtained from Haemophilus paragallinarum has been found useful for preventing avian infectious coryza. This polypeptide induces production of hemagglutination-inhibition antibody and prevents infection and onset of avian infectious coryza. The invention further provides a gene coding for the polypeptide, a recombinant vector for expression of this gene, a host transformed with this vector, a process for preparing the polypeptide in a host, a vaccine for avian infectious coryza comprising the polypeptide as an active ingredient, a monoclonal antibody obtained using the polypeptide as an immunogen, and a diagnostic agent and a therapeutic agent for avian infectious coryza using the peptide and the antibody.Type: GrantFiled: July 11, 2002Date of Patent: July 19, 2005Assignee: Juridical Foundation The Chemo-Sero Therapeutic Research InstituteInventors: Eiji Tokunaga, Masashi Sakaguchi, Kazuo Matsuo, Fukusaburo Hamada, Sachio Tokiyoshi
-
Patent number: 6913755Abstract: This invention is directed to mutant SPE-A toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-A toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-A toxin. The mutant SPE-A toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-A toxin.Type: GrantFiled: December 5, 1997Date of Patent: July 5, 2005Assignee: Regents of the University of MinnesotaInventors: Patrick M. Schlievert, Manuela Roggiani, Jennifer Stoehr Stoehr, Douglas Ohlendorf
-
Patent number: 6896888Abstract: Disease cased by papilloma virus is treated by applying an effective amount of Mycobacterium to the region of infection. Specifically, condylomata acuminata are caused by human papilloma virus infection. Despite numerous treatment modalities these patients often demonstrate recurrent disease. BCG therapy is used in primary treatment or in patients not responding to or recurrent after standard treatment. Six men with rapidly recurrent external and intraurethral condylomata acuminata underwent BCG therapy after initial laser treatment. External application and intraurethral instillation of BCG was performed six times in weekly intervals. Follow-up studies included examination and endoscopic inspection of the urethra and bladder. Three patients completed one course of BCG and had no relapse of condylomata acuminata. Two patients underwent a second course of BCG, of whom one relapsed. One patient relapsed after discontinued therapy due to penile edema. The annual recurrence rate decreased from 3.Type: GrantFiled: April 29, 1999Date of Patent: May 24, 2005Inventors: Andreas Böhle, Dieter Jocham
-
Patent number: 6890539Abstract: A protein from Group B Streptococcus is shown to be an outer surface protein and is a useful target for antimicrobial therapy.Type: GrantFiled: March 11, 2002Date of Patent: May 10, 2005Assignee: Microscience, Ltd.Inventors: Martin John Glenton Hughes, Joseph David Santangelo, Jonathan Douglas Lane, Robert Feldman, Joanne Christine Moore, Richard James Dobson, Paul Everest, Gordon Dougan, Rebecca Kerry Wilson
-
Patent number: 6890910Abstract: This invention provides isolated polynucleotides that encode the MurD protein of Pseudomonas aeruginosa. Purified and isolated MurD recombinant proteins are also provided. Nucleic acid sequences which encode functionally active MurD proteins are described. Assays for the identification of modulators of the of expression of murD and inhibitors of the activity of MurD, are also provided.Type: GrantFiled: May 26, 1999Date of Patent: May 10, 2005Assignee: Merck & Co., Inc.Inventors: Mohammed El-Sherbeini, Barbara Azzolina
-
Patent number: 6891024Abstract: The present invention is directed to particular monoclonal antibodies that find use in the identification and purification of Sarcocystis neurona and related antigens. In particular, these antibodies permit the diagnosis of Sarcocystis related diseases such as equine protozoal myeloencephalitis (EPM).Type: GrantFiled: May 7, 2002Date of Patent: May 10, 2005Assignee: The Curators of the University of MissouriInventor: Antoinette Marsh
-
Patent number: 6884417Abstract: The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molecules in a pharmaceutically acceptable excipient is also contemplated.Type: GrantFiled: May 15, 2001Date of Patent: April 26, 2005Assignee: The Scripps Research InstituteInventors: Theo Kirkland, Peter Tobias, Richard Ulevitch, Ann Moriarty, Didier Leturcq
-
Patent number: 6824985Abstract: Disclosed is an improvement in the analysis for an analyte in a urine test sample in which the urine is contacted with a labeled antibody specific to the analyte and the concentration of the analyte is determined by measuring the response from the label. The improvement involves maintaining the concentration of urea in the test sample above the threshold value which value is the concentration of urea at which increases in the urea concentration do not affect the accuracy of the assay such as by interfering with the binding between the analyte and the labeled antibody.Type: GrantFiled: September 9, 1997Date of Patent: November 30, 2004Assignee: Bayer CorporationInventors: Gary W. Rheinheimer, Meitak Teresa Yip
-
Patent number: 6680061Abstract: The present invention relates to hydrophilic Eimeria polypeptides, DNA-fragments encoding those peptides, recombinant DNA molecules comprising such DNA-fragments, live recombinant carriers comprising such DNA-fragments or recombinant DNA molecules and host cells comprising such DNA-fragments, recombinant DNA molecules or live recombinant carriers. Furthermore, the invention relates to antibodies against the polypeptides and to coccidiosis vaccines based upon said polypeptides. The invention also relates to methods for the preparation of such antibodies and vaccines, and to methods for the detection of Eimeria parasites and antibodies against Eimeria parasites.Type: GrantFiled: December 27, 2000Date of Patent: January 20, 2004Inventors: Theodorus Cornelis Schaap, Catharina Maria Kuiper, Arnoldus Nicolaas Vermeulen
-
Patent number: 6451984Abstract: A stable chicken hybridoma secreting a monoclonal antibody (mAb) that detects the conoid structure of Eimeria acervulina (E. acervulina) sporozoites has been developed. The hybridoma is made by fusing a thymidine kinase (TK)-deficient chicken myeloma with spleen cells from chickens immunized with sporozoite antigen. The monoclonal antibody recognizes sporozoite proteins on the conoid of the anterior tip of E. acervulina sporozoites. The monoclonal antibody has been shown to inhibit the invasion of sporozoites into CD8+ T cells in vitro thereby indicating its role in the recognition of host cells during the invasion process following infection with Eimeria parasites.Type: GrantFiled: September 8, 1995Date of Patent: September 17, 2002Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Hyun S. Lillehoj, B. Nichols Majorie
-
Patent number: 6436633Abstract: A method for screening candidate antimicrobial compounds is described that utilizes a human vaginal xenograft engrafted in a non-human host. The method may be performed by using pathogen inoculated human vaginal xenografts in order to screen a wide range of candidate antimicrobials administered topically or systemically.Type: GrantFiled: October 22, 1999Date of Patent: August 20, 2002Assignee: The Pennsylvania State UniversityInventors: John W. Kreider, Mary K. Howett
-
Patent number: 6410701Abstract: Human neuropeptide receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the neuropeptide receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the neuropeptide receptor nucleic acid sequences and an altered level of the soluble form of the receptors.Type: GrantFiled: June 5, 1995Date of Patent: June 25, 2002Assignee: Human Genome Sciences, Inc.Inventors: Daniel R. Soppet, Yi Li, Craig A. Rosen
-
Patent number: 6379906Abstract: Compositions and methods for the detection of adult Taenia solium and the diagnosis and treatment of T. solium infection are described. The compositions contain one or more adult T. solium polypeptides. The polypeptides are useful as diagnostic agents for the detection of adult tapeworm infection. More preferably, the polypeptides are T. solium glycoprotein antigens referred to herein as T. solium excretory/secretory (TS/ES) polypeptides. The most preferred TS/ES polypeptide has a molecular weight of approximately 33 kDa, 38 kDa, or 42 kDa as determined by SDS-PAGE analysis.Type: GrantFiled: December 6, 1999Date of Patent: April 30, 2002Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Victor C. W. Tsang, Patricia P. Wilkins, James C. Allan
-
Patent number: 5616688Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.Type: GrantFiled: March 7, 1994Date of Patent: April 1, 1997Assignee: The Rockefeller UniversityInventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
-
Patent number: 5510238Abstract: Antigenic proteins may be expressed in bacteria by use of vectors having inserted therein DNA fragments from an envelope gene. The DNA fragments employed in the example are coding sequences found in the HTLV-I envelope gene. The bacteria used was E. coli. The antigenic proteins are useful in identifying antibodies to the organisms from which the DNA fragments were originally obtained.Type: GrantFiled: February 7, 1994Date of Patent: April 23, 1996Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Takis S. Papas, Kenneth Samuel, James A. Lautenberger, Flossie Wong-Staal